Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04120766 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging

Study acronym: SMArT-HS
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 15, 2025 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv10
  2. Primary completion date: Aug 30, 2026 to Sep 1, 2026v9
  3. Primary completion date: Nov 1, 2024 to Aug 30, 2026v8 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Nov 20, 2024 to Nov 30, 2026
    • Eligibility criteria expanded, about 6 words
    • Site details revised
  4. Re-verified, no change to tracked fieldsv7
  5. Eligibility criteria expanded, about 52 words
    • Site contact updated
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date changed from estimate of Dec 2021 to Dec 1, 2021v5
  2. Start date: Nov 2021 to Dec 2021v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Nov 1, 2020 to Nov 2021
    • Study sites: 0 to 1
    • Collaborators expanded, about 5 words
    v3
  4. Lead sponsor: University of Kentucky to Gregory Jicha, MD, PhD
    • Primary completion date: Nov 20, 2023 to Nov 1, 2024
    • Start date: Dec 1, 2019 to Nov 1, 2020
    • Study completion date: Dec 31, 2023 to Nov 20, 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Widespread recognition of the current and projected impact of the dementia epidemic has spurred research into novel drug discovery efforts. It is well recognized by most that Alzheimer's disease is not the only form of dementia and that beginning to turn attention to other disease states is critically important in order to alleviate this burden on the elderly population today This proposal seeks to further progress in this area through the repurposing an existing drug therapy as a potential treatment for Hippocampal Sclerosis of Aging. This disease is seldom recognized clinically and yet is the number one Alzheimer's disease mimic the confounds are diagnostic and treatment of subjects suffering from dementia and as of yet has no potential therapeutic interventions identified. As such, the proposed study represents a cutting-edge, data-driven, low-cost, exploration of a novel disease relevant pathway that may hold promise for global efforts targeting late life dementia which is a major health priority in America today.
Trial Details
NCT Number NCT04120766
Lead Sponsor Gregory Jicha, MD, PhD
Collaborators: National Institute on Aging (NIA)
Conditions
(from sponsor)		 Dementia, Mild Cognitive Impairment
Related terms Cognitive Dysfunction, Dementia, Hippocampal Sclerosis
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov